Unraveling Ceftriaxone Dosing: Free Drug Prediction, Threshold Optimization, and Model Validation.

IF 5 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Johnny Michel, Francesco Monti, Fabien Lamoureux, Djibril Diagouraga, Manuel Etienne, Muriel Quillard, Camille Molkhou, Fabienne Tamion, Sandrine Dahyot, Tania Petersen, Tony Pereira, Martine Pestel-Caron, Julien Grosjean, Thomas Duflot
{"title":"Unraveling Ceftriaxone Dosing: Free Drug Prediction, Threshold Optimization, and Model Validation.","authors":"Johnny Michel, Francesco Monti, Fabien Lamoureux, Djibril Diagouraga, Manuel Etienne, Muriel Quillard, Camille Molkhou, Fabienne Tamion, Sandrine Dahyot, Tania Petersen, Tony Pereira, Martine Pestel-Caron, Julien Grosjean, Thomas Duflot","doi":"10.1208/s12248-025-01041-w","DOIUrl":null,"url":null,"abstract":"<p><p>Ceftriaxone is pivotal in treating severe infections; however, predicting unbound plasma ceftriaxone (CEF<sub>u</sub>) from total ceftriaxone (CEF<sub>tot</sub>) remains challenging. This study aimed to (1) predict CEF<sub>u</sub> from CEF<sub>tot</sub>, (2) determine optimal target for CEF<sub>tot</sub> trough concentration in plasma, (3) perform an external validation of published models, and (4) to ascertain whether the CEF dosing regimen was sufficient to achieve the therapeutic objectives. CEF<sub>u</sub> predictions based on CEF<sub>tot</sub> were evaluated using previously published models. Optimal CEF<sub>tot</sub> targets for an MIC of 1mg/L were calculated to achieve CEF<sub>u</sub> concentrations above MIC and 4xMIC 100% of the time. External validation was conducted assessing serum albumin, CEF<sub>tot</sub> and CEF<sub>u</sub> and comparing predicted CEF<sub>u</sub> across models. Retrospective data, comprising 408 CEF<sub>tot</sub> from 222 patients, were analyzed to assess the probability of target attainment (PTA) based on model predicted CEF<sub>u</sub>. CEF<sub>u</sub> predictions based on CEF<sub>tot</sub> were evaluated using previously published models. Optimal CEF<sub>tot</sub> targets for an MIC of 1mg/L were calculated to achieve CEF<sub>u</sub> concentrations above MIC and 4xMIC 100% of the time. External validation was conducted assessing serum albumin, CEF<sub>tot</sub> and CEF<sub>u</sub> and comparing predicted CEF<sub>u</sub> across models. Retrospective data, comprising 408 CEF<sub>tot</sub> from 222 patients, were analyzed to assess the probability of target attainment (PTA) based on model predicted CEF<sub>u</sub>. Optimal CEF<sub>tot</sub> trough concentration targets ranged from 2.0 mg/L to 16.9 mg/L (1xMIC) and from 7.9 mg/L to 56.2 mg/L (4xMIC) across models. Some models accurately predicted CEF<sub>u</sub> obtained from prospective external validation. In the retrospective cohort, PTA ranged from 94.4% to 98.7% for 1xMIC and from 66.9% to 97.3% for 4xMIC. Modeling or direct quantification of CEF<sub>u</sub> may improve patient outcomes, but achieving this requires standardized analytical approaches and further research to assess the ability of published models to accurately predict CEF<sub>u</sub>.</p>","PeriodicalId":50934,"journal":{"name":"AAPS Journal","volume":"27 2","pages":"50"},"PeriodicalIF":5.0000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAPS Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1208/s12248-025-01041-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Ceftriaxone is pivotal in treating severe infections; however, predicting unbound plasma ceftriaxone (CEFu) from total ceftriaxone (CEFtot) remains challenging. This study aimed to (1) predict CEFu from CEFtot, (2) determine optimal target for CEFtot trough concentration in plasma, (3) perform an external validation of published models, and (4) to ascertain whether the CEF dosing regimen was sufficient to achieve the therapeutic objectives. CEFu predictions based on CEFtot were evaluated using previously published models. Optimal CEFtot targets for an MIC of 1mg/L were calculated to achieve CEFu concentrations above MIC and 4xMIC 100% of the time. External validation was conducted assessing serum albumin, CEFtot and CEFu and comparing predicted CEFu across models. Retrospective data, comprising 408 CEFtot from 222 patients, were analyzed to assess the probability of target attainment (PTA) based on model predicted CEFu. CEFu predictions based on CEFtot were evaluated using previously published models. Optimal CEFtot targets for an MIC of 1mg/L were calculated to achieve CEFu concentrations above MIC and 4xMIC 100% of the time. External validation was conducted assessing serum albumin, CEFtot and CEFu and comparing predicted CEFu across models. Retrospective data, comprising 408 CEFtot from 222 patients, were analyzed to assess the probability of target attainment (PTA) based on model predicted CEFu. Optimal CEFtot trough concentration targets ranged from 2.0 mg/L to 16.9 mg/L (1xMIC) and from 7.9 mg/L to 56.2 mg/L (4xMIC) across models. Some models accurately predicted CEFu obtained from prospective external validation. In the retrospective cohort, PTA ranged from 94.4% to 98.7% for 1xMIC and from 66.9% to 97.3% for 4xMIC. Modeling or direct quantification of CEFu may improve patient outcomes, but achieving this requires standardized analytical approaches and further research to assess the ability of published models to accurately predict CEFu.

求助全文
约1分钟内获得全文 求助全文
来源期刊
AAPS Journal
AAPS Journal 医学-药学
CiteScore
7.80
自引率
4.40%
发文量
109
审稿时长
1 months
期刊介绍: The AAPS Journal, an official journal of the American Association of Pharmaceutical Scientists (AAPS), publishes novel and significant findings in the various areas of pharmaceutical sciences impacting human and veterinary therapeutics, including: · Drug Design and Discovery · Pharmaceutical Biotechnology · Biopharmaceutics, Formulation, and Drug Delivery · Metabolism and Transport · Pharmacokinetics, Pharmacodynamics, and Pharmacometrics · Translational Research · Clinical Evaluations and Therapeutic Outcomes · Regulatory Science We invite submissions under the following article types: · Original Research Articles · Reviews and Mini-reviews · White Papers, Commentaries, and Editorials · Meeting Reports · Brief/Technical Reports and Rapid Communications · Regulatory Notes · Tutorials · Protocols in the Pharmaceutical Sciences In addition, The AAPS Journal publishes themes, organized by guest editors, which are focused on particular areas of current interest to our field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信